Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Percutaneous Systems Inc. (PercSys)

This article was originally published in Start Up

Executive Summary

Stone disease is among the most painful and prevalent of urologic disorders, affecting more than 5% of the US population. The most common intervention for kidney and ureteral stones involves manipulation, irrigation and fragmentation through an endoscope. However, such procedures may cause the stone itself or stone fragments to migrate within the urinary tract. Current devices to reduce migration are difficult to place and remove, and they do not adequately conform to the ureter. These products also do not provide a fluid-tight seal. In contrast, the PercSys Accordion stone management device from Percutaneous Systems (PercSys) effectively eliminates stone migration and facilitates fragment removal. The microcatheter system forms an occlusion in the ureter to prevent stone migration, has been shown to increase fragmentation efficiency, and has demonstrated its ability to sweep multiple fragments.

You may also be interested in...

Start-Up Previews (05/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Medical Dermatology Gets Under VCs' Skin," features profiles of Garnet Biotherapeutics, Medimetriks and Topica Pharmaceuticals. Plus these Start-Ups Across Health Care: Carolus Therapeutics, Forma Therapeutics, NovaLign Orthopaedics, OmegaGenesis and PercSys.

Health And Wellness Trademark Review 3 December, 2019

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts